{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:22:17Z","timestamp":1720052537946},"reference-count":29,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,2]]},"DOI":"10.7759\/cureus.63712","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:02:22Z","timestamp":1719982942000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of Intravitreal Ranibizumab and Laser Photocoagulation in the Treatment of Type I Retinopathy of Prematurity in Malaysia: A One-Year Follow-Up Study"],"prefix":"10.7759","author":[{"given":"Jami","family":"Wardati H","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Khadijah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Nurul-Farhana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahit","family":"Karimmah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoon Kit Ivan","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Md Razali","family":"Syahmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona Lee Min","family":"Chew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamalia","family":"Rahmat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norhafizah","family":"Hamzah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Shatriah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(52)91140-9","article-title":"Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations","volume":"35","author":"Patz A","year":"1952","unstructured":"Patz A, Hoeck Le, De La Cruz E. Studies on the effect of high oxygen administration in retrolental fibroplasia. I. Nursery observations. Am J Ophthalmol. 1952, 35:1248-53. 10.1016\/0002-9394(52)91140-9","journal-title":"Am J Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2013.01.006","article-title":"Nutrition, insulin-like growth factor-1 and retinopathy of prematurity","volume":"18","author":"H\u00e5rd AL","year":"2013","unstructured":"H\u00e5rd AL, Smith LE, Hellstr\u00f6m A. Nutrition, insulin-like growth factor-1 and retinopathy of prematurity. Semin Fetal Neonatal Med. 2013, 18:136-42. 10.1016\/j.siny.2013.01.006","journal-title":"Semin Fetal Neonatal Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1996.01100130413008","article-title":"Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1\/2 years after randomization","volume":"114","year":"1996","unstructured":"Multicenter trial of cryotherapy for retinopathy of prematurity. Snellen visual acuity and structural outcome at 5 1\/2 years after randomization. Arch Ophthalmol. 1996, 114.417-24. 10.1001\/archopht.1996.01100130413008","journal-title":"Arch Ophthalmol"},{"key":"ref4","article-title":"Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial","volume":"102","author":"Good WV","year":"2004","unstructured":"Good WV. Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc. 2004, 102:233-50.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner HA","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011, 364:603-15. 10.1056\/NEJMoa1007374","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-4642(21)00195-4","article-title":"2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial","volume":"5","author":"Marlow N","year":"2021","unstructured":"Marlow N, Stahl A, Lepore D, et al.. 2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study): prospective follow-up of an open label, randomised controlled trial. Lancet Child Adolesc Health. 2021, 5:698-707. 10.1016\/S2352-4642(21)00195-4","journal-title":"Lancet Child Adolesc Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312272","article-title":"Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety","volume":"103","author":"Kang HG","year":"2019","unstructured":"Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC, Kim M. Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety. Br J Ophthalmol. 2019, 103:1332-6. 10.1136\/bjophthalmol-2018-312272","journal-title":"Br J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial","volume":"394","author":"Stahl A","year":"2019","unstructured":"Stahl A, Lepore D, Fielder A, et al.. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial. Lancet. 2019, 394:1551-9. 10.1016\/S0140-6736(19)31344-3","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery RL","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC, et al.. Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab. Retina. 2017, 37:1847-58. 10.1097\/IAE.0000000000001493","journal-title":"Retina"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.32007","article-title":"A review on the incidence and related risk factors of retinopathy of prematurity across various countries","volume":"14","author":"Nair A","year":"2022","unstructured":"Nair A, El Ballushi R, Anklesaria BZ, Kamali M, Talat M, Watts T. A review on the incidence and related risk factors of retinopathy of prematurity across various countries. Cureus. 2022, 14:e32007. 10.7759\/cureus.32007","journal-title":"Cureus"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2011.19","article-title":"Childhood blindness and severe visual impairment in Malaysia: a nationwide study","volume":"25","author":"Patel DK","year":"2011","unstructured":"Patel DK, Tajunisah I, Gilbert C, Subrayan V. Childhood blindness and severe visual impairment in Malaysia: a nationwide study. Eye (Lond). 2011, 25:436-42. 10.1038\/eye.2011.19","journal-title":"Eye (Lond)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.05.031","article-title":"International classification of retinopathy of prematurity, third edition","volume":"128","author":"Chiang MF","year":"2021","unstructured":"Chiang MF, Quinn GE, Fielder AR, et al.. International classification of retinopathy of prematurity, third edition. Ophthalmology. 2021, 128:e51-68. 10.1016\/j.ophtha.2021.05.031","journal-title":"Ophthalmology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05137-9","article-title":"Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity","volume":"259","author":"Murakami T","year":"2021","unstructured":"Murakami T, Sugiura Y, Okamoto F, et al.. Comparison of 5-year safety and efficacy of laser photocoagulation and intravitreal bevacizumab injection in retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2021, 259:2849-55. 10.1007\/s00417-021-05137-9","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2016.1196709","article-title":"Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey","volume":"42","author":"Gunay M","year":"2017","unstructured":"Gunay M, Sukgen EA, Celik G, Kocluk Y. Comparison of bevacizumab, ranibizumab, and laser photocoagulation in the treatment of retinopathy of prematurity in Turkey. Curr Eye Res. 2017, 42:462-9. 10.1080\/02713683.2016.1196709","journal-title":"Curr Eye Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.51847\/6vtXeVdItu","article-title":"Comparative analysis of intravitreal ranibizumab versus laser therapy for retinopathy of prematurity","volume":"13","author":"Elabbasy A","year":"2022","unstructured":"Elabbasy A, Abdelbaky M, Al-Shehri H, et al.. Comparative analysis of intravitreal ranibizumab versus laser therapy for retinopathy of prematurity. Arch Pharm Pract. 2022, 13:30-6. 10.51847\/6vtXeVdItu","journal-title":"Arch Pharm Pract"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001241","article-title":"Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity","volume":"37","author":"Zhang G","year":"2017","unstructured":"Zhang G, Yang M, Zeng J, et al.. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity. Retina. 2017, 37:710-7. 10.1097\/IAE.0000000000001241","journal-title":"Retina"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.028","article-title":"Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor","volume":"128","author":"Barry GP","year":"2021","unstructured":"Barry GP, Yu Y, Ying GS, Tomlinson LA, Lajoie J, Fisher M, Binenbaum G. Retinal detachment after treatment of retinopathy of prematurity with laser versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2021, 128:1188-96. 10.1016\/j.ophtha.2020.12.028","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2022.08.524","article-title":"Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity","volume":"26","author":"Hoppe C","year":"2022","unstructured":"Hoppe C, Holt DG, Arnold BF, Thinda S, Padmanabhan SP, Oatts JT. Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity. J AAPOS. 2022, 26:305.e1-6. 10.1016\/j.jaapos.2022.08.524","journal-title":"J AAPOS"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-023-01543-3","article-title":"The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis","volume":"49","author":"Chen J","year":"2023","unstructured":"Chen J, Hao Q, Zhang J, Du Y, Chen H, Cheng X. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis. Ital J Pediatr. 2023, 49:136. 10.1186\/s13052-023-01543-3","journal-title":"Ital J Pediatr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02886-5","article-title":"Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity","volume":"23","author":"Cao JK","year":"2023","unstructured":"Cao JK, Han T, Tang HY, Zhang S, Wang ZH, Feng ZC, Li QP. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity. BMC Ophthalmol. 2023, 23:137. 10.1186\/s12886-023-02886-5","journal-title":"BMC Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1202927","article-title":"Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis","volume":"11","author":"Alva N","year":"2023","unstructured":"Alva N, Mart\u00ednez AR, Ortiz-Saavedra B, et al.. Ranibizumab for the treatment of retinopathy of prematurity: systematic review and meta-analysis. Front Pediatr. 2023, 11:1202927. 10.3389\/fped.2023.1202927","journal-title":"Front Pediatr"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaapos.2019.05.013","article-title":"Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab","volume":"23","author":"Barry GP","year":"2019","unstructured":"Barry GP, Tauber KA, Fisher M, Greenberg S, Zobal-Ratner J, Binenbaum G. Short-term retinal detachment risk after treatment of type 1 retinopathy of prematurity with laser photocoagulation versus intravitreal bevacizumab. J AAPOS. 2019, 23:260.e1-4. 10.1016\/j.jaapos.2019.05.013","journal-title":"J AAPOS"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.911095","article-title":"Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China","volume":"9","author":"Linghu D","year":"2022","unstructured":"Linghu D, Cheng Y, Zhu X, et al.. Comparison of intravitreal anti-VEGF agents with laser photocoagulation for retinopathy of prematurity of 1,627 eyes in China. Front Med (Lausanne). 2022, 9:911095. 10.3389\/fmed.2022.911095","journal-title":"Front Med (Lausanne)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-018-0685-6","article-title":"Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP)","volume":"18","author":"Li Z","year":"2018","unstructured":"Li Z, Zhang Y, Liao Y, Zeng R, Zeng P, Lan Y. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in type-1 and threshold retinopathy of prematurity (ROP). BMC Ophthalmol. 2018, 18:19. 10.1186\/s12886-018-0685-6","journal-title":"BMC Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1159\/000316134","article-title":"Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro","volume":"45","author":"Xiang N","year":"2011","unstructured":"Xiang N, Zhao MJ, Li XY, Zheng HH, Li GG, Li B. Redundant mechanisms for vascular growth factors in retinopathy of prematurity in vitro. Ophthalmic Res. 2011, 45:92-101. 10.1159\/000316134","journal-title":"Ophthalmic Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208129","article-title":"Mechanisms and management of retinopathy of prematurity","volume":"367","author":"Hartnett ME","year":"2012","unstructured":"Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012, 367:2515-26. 10.1056\/NEJMra1208129","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0b013e3182279cfa","article-title":"Prentice Award Lecture 2010: a case for peripheral optical treatment strategies for myopia","volume":"88","author":"Smith EL 3rd","year":"2011","unstructured":"Smith EL 3rd. Prentice Award Lecture 2010: a case for peripheral optical treatment strategies for myopia. Optom Vis Sci. 2011, 88:1029-44. 10.1097\/OPX.0b013e3182279cfa","journal-title":"Optom Vis Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.05.10","article-title":"Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity","volume":"15","author":"Zou Q","year":"2022","unstructured":"Zou Q, Zhu YQ, Zhang FJ, Liu QP. Efficacy evaluation of intravitreal ranibizumab therapy for three types of retinopathy of prematurity. Int J Ophthalmol. 2022, 15:753-9. 10.18240\/ijo.2022.05.10","journal-title":"Int J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.04.028","article-title":"Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy","volume":"123","author":"Mintz-Hittner HA","year":"2016","unstructured":"Mintz-Hittner HA, Geloneck MM, Chuang AZ. Clinical management of recurrent retinopathy of prematurity after intravitreal bevacizumab monotherapy. Ophthalmology. 2016, 123:1845-55. 10.1016\/j.ophtha.2016.04.028","journal-title":"Ophthalmology"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/265954-comparison-of-intravitreal-ranibizumab-and-laser-photocoagulation-in-the-treatment-of-type-i-retinopathy-of-prematurity-in-malaysia-a-one-year-follow-up-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T05:02:29Z","timestamp":1719982949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/265954-comparison-of-intravitreal-ranibizumab-and-laser-photocoagulation-in-the-treatment-of-type-i-retinopathy-of-prematurity-in-malaysia-a-one-year-follow-up-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,2]]},"references-count":29,"URL":"https:\/\/doi.org\/10.7759\/cureus.63712","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,2]]}}}